on CROSSJECT (EPA:ALCJ)
CROSSJECT Expands Leadership for New Industrial and Commercial Phase
CROSSJECT has announced a strategic expansion of its Executive Board, now comprising five members: Olivier Lacombe, Didier Morin, Lionel Seltz, Patrick Alexandre, and Isabelle Liebschutz. This restructuring aims to strengthen the company's governance as it moves towards the industrialization and distribution of its innovative ZENEO® needle-free auto-injector technology.
The company's focus is shifting from securing FDA registration for its ZEPIZURE® product to scaling industrial operations and building its U.S. commercial presence. The expanded board represents key areas including pharmaceutical development, industrial operations, and financial management, reflecting CROSSJECT's commitment to effective execution during this critical phase.
Additionally, CROSSJECT US has enhanced its regulatory leadership by appointing David Pudwill as Vice President, Regulatory & Scientific Affairs, reinforcing its efforts in the American market.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all CROSSJECT news